A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects
Status:
Completed
Trial end date:
2013-07-20
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of ASP015K monotherapy and to evaluate the
dose-dependent response of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects
given ASP015K for 12 weeks.